News for 10x Genomics, Inc. (0A88.L)

Shares of 10x Genomics Inc (TXG) fell 4.65% in mid-day trading on Jul 21. The stock reached an intraday low of $11.45, before recovering slightly to $11.59,

Summary On July 17, 2025, 10x Genomics Inc (TXG), a leader in single cell and spatial biology, announced a collaboration with the A*STAR Genome Institute of Sin

PR NewswirePLEASANTON, Calif. and SINGAPORE, July 17, 2025 Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeu

PR NewswirePLEASANTON, Calif., July 10, 2025 PLEASANTON, Calif., July 10, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell an

10x Genomics (TXG) is set to release its Q2 2025 financial results on August 7, 2025, after market close. A conference call and live webcast for analyst

Shares of 10x Genomics Inc (TXG) fell 7.49% in mid-day trading on Jul 7. The stock reached an intraday low of $11.97, before recovering slightly to $12.04,

Shares of 10x Genomics Inc (TXG) surged 4.23% in mid-day trading on Jul 2. The stock reached an intraday high of $12.82, before settling at $12.57, up from

On June 26, 2025, B of A Securities analyst Derik De Bruin announced an update for 10x Genomics (TXG). The analyst decided to maintain the 'Neutral' rating for

Bank of America analyst Michael Ryskin has revised the price target for 10x Genomics (TXG), raising it from $12 to $13 while maintaining a Neutral rating on the

10x Genomics, Inc. rebounds post-Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a global settlement agreement with Bruker Corporation, which resolves all outstanding patent litigation between the two firms. As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 […]

Shares of 10x Genomics Inc (TXG) surged 4.12% in mid-day trading on Jun 18. The stock reached an intraday high of $11.01, before settling at $11.00, up from

On June 4, 2025, Scotiabank's analyst Eric Winmill maintained his

In a strategic move, Cathie Wood's ARK Investment Management has expanded its position in the genomics sector by purchasing 290,000 shares of 10x Genomics (TXG)

June 3 - Cathie Wood's Ark Invest sold 1,594 shares of Tesla Inc (TSLA) through its ARK Innovation ETF (ARKK), offloading a position worth $546,247, according t

ARK Investment, led by Cathie Wood, has made a substantial investment in 10x Genomics (TXG) by purchasing 335,000 shares. This move underscores ARK's confidence

On Monday, Cathie Wood-led Ark Invest sold shares of Tesla and Palantir, amidst competition and data misuse concerns. Ark also made significant trades in other companies, such as eToro and Illumina.

ARK Investment Management, led by Cathie Wood, has expanded its holdings by purchasing 342,000 shares of 10x Genomics (TXG). This acquisition reflects ARK's ong

Cathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham.